Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses
Date:7/7/2008

of the forward-looking statements contained in this press release to reflect future results, events or developments.

Additional Information and Where to Find It

-------------------------------------------

This communication may be deemed to be solicitation material in respect of the proposed investment of Ares Corporate Opportunities Fund III, L.P., New Leaf Ventures I, L.P. and New Leaf Ventures II, L.P. in Angiotech Pharmaceuticals, Inc.'s ("Angiotech") subsidiary, Angiotech Pharmaceutical Interventions, Inc. In connection with the proposed investment, Angiotech intends to file relevant materials with the SEC, including a proxy statement on Schedule 14A. SHAREHOLDERS OF ANGIOTECH ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING ANGIOTECH'S PROXY STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents free of charge at the SEC's web site, http://www.sec.gov, and Angiotech shareholders will receive information at an appropriate time on how to obtain transaction-related documents for free from Angiotech. Such documents are not currently available.

Participants in Solicitation

----------------------------

Angiotech and its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the holders of Angiotech common shares in respect of the proposed transaction. Information about the directors and executive officers of Angiotech is set forth in Angiotech's Annual Report on Form 40-F for the most recently ended fiscal year, which was filed with the SEC on March 31, 2008. Investors may obtain additional information regarding the interest of such participants by reading the proxy statement regarding the acquisition when it becomes available.

About Angiotech

Angiotec
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
(Date:1/14/2014)... 2014 During the 1600’s through the 1800’s ... Doctor’s Plague.” In this time period, doctors did not know ... times, to the death of vulnerable patients. In the same ... they may be unwittingly transmitting herpes viruses to their patients. ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... IP Ownership into Discussion , ... Reston, VA (PRWEB) ... of data integrity solutions, announced today that is has joined the ... protection provider of its kind within the alliance. , , ...
... Ipilimumab to be Presented -PRINCETON, N.J., April 29 ... that the following clinical abstracts for ipilimumab in melanoma ... antibody for cancer treatment, have been selected to be ... the American Society of Clinical Oncology, being held May ...
... of Net Product Sales; Quarter Highlighted by Nearly $7 Million ... Pa., April 29 ViroPharma Incorporated (Nasdaq: VPHM ... ended March 31, 2009., , ... income of $11.5 million, and GAAP net loss of $59.2 ...
Cached Biology Technology:Surety, LLC Joins Microsoft BioIT Alliance 2Surety, LLC Joins Microsoft BioIT Alliance 3Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 2Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 3Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 4ViroPharma Incorporated Reports First Quarter 2009 Financial Results 2ViroPharma Incorporated Reports First Quarter 2009 Financial Results 3ViroPharma Incorporated Reports First Quarter 2009 Financial Results 4ViroPharma Incorporated Reports First Quarter 2009 Financial Results 5ViroPharma Incorporated Reports First Quarter 2009 Financial Results 6ViroPharma Incorporated Reports First Quarter 2009 Financial Results 7ViroPharma Incorporated Reports First Quarter 2009 Financial Results 8ViroPharma Incorporated Reports First Quarter 2009 Financial Results 9ViroPharma Incorporated Reports First Quarter 2009 Financial Results 10ViroPharma Incorporated Reports First Quarter 2009 Financial Results 11ViroPharma Incorporated Reports First Quarter 2009 Financial Results 12ViroPharma Incorporated Reports First Quarter 2009 Financial Results 13ViroPharma Incorporated Reports First Quarter 2009 Financial Results 14ViroPharma Incorporated Reports First Quarter 2009 Financial Results 15
(Date:4/23/2014)... allergies and other chronic inflammatory disorders among people of ... their reduced exposure to the microbes that thrive in ... The article, published in the journal Clinical & ... centers who have less access to green spaces may ... caused by immune system dysfunction. , When our immune ...
(Date:4/23/2014)... French and German . ... and other mammals, the difference between sexes depends on one single ... in males, where the two sexual chromosomes are X and Y, ... responsible for all the morphological and physiological differences between males and ... very long time ago, the X and Y were identical, until ...
(Date:4/23/2014)... Like a hungry diner ripping open a dinner roll, ... must tear open a hydrogen molecule. Now researchers have ... the two halves of its hydrogen feast. The view ... make the catalyst work better for alternative energy uses. ... shown precisely where the hydrogen halves end up in ...
Breaking Biology News(10 mins):Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3Male or female? 2Male or female? 3Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4
... to play a pivotal role in the inception of Darwin’s ... of their significance when he collected them during his voyage ... to predict the impact the vast amount of marine microbial ... by J. Craig Venter, Ph.D., and his team ?will have ...
... option for treating atrial fibrillation, a common irregular heart ... University School of Medicine in St. Louis have developed ... a complex surgical procedure that has had the best ... simplified procedure is termed Cox-maze IV, and the surgeons ...
... have large outbreaks of Ebola virus killed tens of ... Observations published in the May issue of The American ... amplified by Ebola transmission between ape social groups. The ... the devastating impact of Ebola on wild apes. ...
Cached Biology News:Darwin's famous finches and Venter's marine microbes 2Darwin's famous finches and Venter's marine microbes 3Darwin's famous finches and Venter's marine microbes 4Darwin's famous finches and Venter's marine microbes 5Surgeons develop simpler way to cure atrial fibrillation 2Ebola outbreaks killing thousands of gorillas and chimpanzees 2
The Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 6 microcentrifuge tubes....
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by the lipoxygenation of linoleic acid ... detected in atherosclerotic plaques, as an esterified component ...
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
...
Biology Products: